Combinatorial immunotherapy strategies: most gods throw dice, but fate
Abstract
Immuno-oncology drugs (IODs) are considered as game-changing treatments in oncology, because diseases with once dismal prognosis such as metastatic melanoma or lung cancer now show 3-year survival rates in the 20-40% range. However, it has to be kept in mind
Origin : Files produced by the author(s)